NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Characterization of Skin Immunity to Aedes Aegypti Saliva in Dengue-endemic Participants in Cambodia

Phase 1

Completed

Conditions: Vector Borne Diseases

Interventions: Other: Mosquito Feeding

First Posted Date: 2020-04-17

Last Posted Date: 2022-04-12

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 42

Registration Number: NCT04350905

Locations: 🇰🇭
Kampong Speu Referral Hoispital, Chbar Mon, Cambodia

Safety and Efficacy Study of Meningococcal Group B Vaccine rMenB+OMV NZ (Bexsero) to Prevent Gonococcal Infection

Phase 2

Active, not recruiting

Conditions: Gonococcal Infection

Interventions: Other: Placebo
Biological: Meningococcal Group B Vaccine

First Posted Date: 2020-04-16

Last Posted Date: 2025-01-10

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 2606

Registration Number: NCT04350138

Locations: 🇺🇸
UCLA Clinical AIDS Research and Education (CARE) Center, Los Angeles, California, United States
🇺🇸
SFDPH Bridge HIV Center, San Francisco, California, United States
🇺🇸
Emory University School of Medicine - The Ponce de Leon Center, Atlanta, Georgia, United States

and more 10 locations

Collection of Anti-SARS-CoV-2 Immune Plasma

Completed

Conditions: Coronavirus Disease 2019 (COVID-19)

First Posted Date: 2020-04-14

Last Posted Date: 2021-03-05

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 151

Registration Number: NCT04344977

Locations: 🇺🇸
Lundquist Institute for Biomedical Innovation at Harbor - UCLA Medical Center, Torrance, California, United States
🇺🇸
Bloodworks Northwest, Seattle, Washington, United States
🇺🇸
University of Miami Infectious Diseases Research Unit, Miami, Florida, United States

Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption

Phase 1

Recruiting

Conditions: HIV Infection

Interventions: Biological: N-803 (IL-15 Superagonist)
Biological: VRC07-523LS
Biological: 10-1074

First Posted Date: 2020-04-09

Last Posted Date: 2024-10-08

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 46

Registration Number: NCT04340596

Locations: 🇺🇸
Alabama CRS (Site ID# 31788), Birmingham, Alabama, United States
🇺🇸
UCLA CARE Center CRS, Los Angeles, California, United States
🇺🇸
UCSD Antiviral Research Center CRS (Site ID: 701), San Diego, California, United States

and more 12 locations

Evaluation of AMG 714 for Vitiligo

Phase 2

Active, not recruiting

Conditions: Vitiligo

Interventions: Biological: AMG 714
Biological: Placebo
Procedure: nbUVB phototherapy

First Posted Date: 2020-04-08

Last Posted Date: 2024-11-25

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 57

Registration Number: NCT04338581

Locations: 🇺🇸
University of California, Irvine: Department of Dermatology, Irvine, California, United States
🇺🇸
Tufts Medical Center: Department of Dermatology, Boston, Massachusetts, United States
🇺🇸
Perelman School of Medicine, University of Pennsylvania: Department of Dermatology, Philadelphia, Pennsylvania, United States

and more 5 locations

Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV

Phase 2

Withdrawn

Conditions: HIV Infections

Interventions: Drug: Cenicriviroc Mesylate (CVC)
Drug: Placebo

First Posted Date: 2020-04-06

Last Posted Date: 2022-12-21

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Registration Number: NCT04334915

SARS-COV2 Pandemic Serosurvey and Blood Sampling

Completed

Conditions: SARS-COV2 Virus

First Posted Date: 2020-04-06

Last Posted Date: 2024-01-26

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 11363

Registration Number: NCT04334954

Locations: 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Safety and Efficacy of CIS43LS Anti-malaria mAb in Mali

Phase 2

Completed

Conditions: Malaria
Plasmodium Falciparum Infection

Interventions: Other: Normal saline
Biological: VRC-MALMAB0100-00-AB (CIS43LS)

First Posted Date: 2020-04-01

Last Posted Date: 2024-05-02

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 348

Registration Number: NCT04329104

Locations: 🇲🇱
Torodo MRTC Clinic, Torodo, Région De Koulikoro, Mali
🇲🇱
Kalifabougou MRTC Clinic, Kalifabougou, Région De Koulikoro, Mali

Evaluation and Follow-up of People With Tick-borne Diseases

Withdrawn

Conditions: Lyme Disease
Tick-Borne Disease

First Posted Date: 2020-03-24

Last Posted Date: 2023-11-18

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Registration Number: NCT04318925

Locations: 🇺🇸
University of Maryland Baltimore, Department of Medicine, Baltimore, Maryland, United States

Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study

Phase 2

Completed

Conditions: HIV
Tuberculosis

Interventions: Drug: Clofazimine (CFZ)
Drug: Rifapentine (RPT)
Drug: Ethambutol (EMB)
Drug: Isoniazid (INH)
Drug: Rifampicin (RIF)
Drug: Pyrazinamide (PZA)
Dietary Supplement: Pyridoxine (vitamin B6)

First Posted Date: 2020-03-17

Last Posted Date: 2024-07-03

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 104

Registration Number: NCT04311502

Locations: 🇭🇹
Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS, Port-au-Prince, Haiti
🇿🇼
Milton Park CRS, Harare, Zimbabwe
🇿🇦
CAPRISA eThekwini CRS, Durban, Kwa Zulu Natal, South Africa

and more 3 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy